217 related articles for article (PubMed ID: 22283718)
1. Obinutuzumab for the treatment of lymphoproliferative disorders.
Owen C; Stewart DA
Expert Opin Biol Ther; 2012 Mar; 12(3):343-51. PubMed ID: 22283718
[TBL] [Abstract][Full Text] [Related]
2. Obinutuzumab for B-cell malignancies.
Owen CJ; Stewart DA
Expert Opin Biol Ther; 2014 Aug; 14(8):1197-205. PubMed ID: 24856933
[TBL] [Abstract][Full Text] [Related]
3. Obinutuzumab in hematologic malignancies: lessons learned to date.
Illidge T; Klein C; Sehn LH; Davies A; Salles G; Cartron G
Cancer Treat Rev; 2015 Nov; 41(9):784-92. PubMed ID: 26190254
[TBL] [Abstract][Full Text] [Related]
4. Obinutuzumab: a new class of anti-CD20 monoclonal antibody.
Gagez AL; Cartron G
Curr Opin Oncol; 2014 Sep; 26(5):484-91. PubMed ID: 25014645
[TBL] [Abstract][Full Text] [Related]
5. Obinutuzumab for chronic lymphocytic leukemia.
Rioufol C; Salles G
Expert Rev Hematol; 2014 Oct; 7(5):533-43. PubMed ID: 25163491
[TBL] [Abstract][Full Text] [Related]
6. Obinutuzumab in follicular lymphoma.
Martinez-Calle N; Figueroa-Mora R; Villar-Fernandez S; Marcos-Jubilar M; Panizo C
Drugs Today (Barc); 2016 Dec; 52(12):643-651. PubMed ID: 28276536
[TBL] [Abstract][Full Text] [Related]
7. Obinutuzumab (GA101) compared to rituximab significantly enhances cell death and antibody-dependent cytotoxicity and improves overall survival against CD20(+) rituximab-sensitive/-resistant Burkitt lymphoma (BL) and precursor B-acute lymphoblastic leukaemia (pre-B-ALL): potential targeted therapy in patients with poor risk CD20(+) BL and pre-B-ALL.
Awasthi A; Ayello J; Van de Ven C; Elmacken M; Sabulski A; Barth MJ; Czuczman MS; Islam H; Klein C; Cairo MS
Br J Haematol; 2015 Dec; 171(5):763-75. PubMed ID: 26471982
[TBL] [Abstract][Full Text] [Related]
8. Obinutuzumab (GA101) for the treatment of chronic lymphocytic leukemia and other B-cell non-hodgkin's lymphomas: a glycoengineered type II CD20 antibody.
Goede V; Klein C; Stilgenbauer S
Oncol Res Treat; 2015; 38(4):185-92. PubMed ID: 25877943
[TBL] [Abstract][Full Text] [Related]
9. Combination therapy with the type II anti-CD20 antibody obinutuzumab.
Klein C; Bacac M; Umana P; Fingerle-Rowson G
Expert Opin Investig Drugs; 2017 Oct; 26(10):1145-1162. PubMed ID: 28845710
[TBL] [Abstract][Full Text] [Related]
10. Update on obinutuzumab in the treatment of B-cell malignancies.
Illidge T; Cheadle EJ; Donaghy C; Honeychurch J
Expert Opin Biol Ther; 2014 Oct; 14(10):1507-17. PubMed ID: 25190612
[TBL] [Abstract][Full Text] [Related]
11. GA-101, a third-generation, humanized and glyco-engineered anti-CD20 mAb for the treatment of B-cell lymphoid malignancies.
Robak T
Curr Opin Investig Drugs; 2009 Jun; 10(6):588-96. PubMed ID: 19513948
[TBL] [Abstract][Full Text] [Related]
12. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention.
Jazirehi AR; Bonavida B
Oncogene; 2005 Mar; 24(13):2121-43. PubMed ID: 15789036
[TBL] [Abstract][Full Text] [Related]
13. Obinutuzumab for the treatment of chronic lymphocytic leukemia and other B-cell lymphoproliferative disorders.
Said R; Tsimberidou AM
Expert Opin Biol Ther; 2017 Nov; 17(11):1463-1470. PubMed ID: 28893099
[TBL] [Abstract][Full Text] [Related]
14. Obinutuzumab for relapsed or refractory indolent non-Hodgkin's lymphomas.
Gabellier L; Cartron G
Ther Adv Hematol; 2016 Apr; 7(2):85-93. PubMed ID: 27054024
[TBL] [Abstract][Full Text] [Related]
15. A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies.
Tobinai K; Klein C; Oya N; Fingerle-Rowson G
Adv Ther; 2017 Feb; 34(2):324-356. PubMed ID: 28004361
[TBL] [Abstract][Full Text] [Related]
16. Obinutuzumab for the treatment of indolent lymphoma.
Edelmann J; Gribben JG
Future Oncol; 2016 Aug; 12(15):1769-81. PubMed ID: 27117452
[TBL] [Abstract][Full Text] [Related]
17. Intratumoral but not systemic delivery of CpG oligodeoxynucleotide augments the efficacy of anti-CD20 monoclonal antibody therapy against B cell lymphoma.
Betting DJ; Yamada RE; Kafi K; Said J; van Rooijen N; Timmerman JM
J Immunother; 2009; 32(6):622-31. PubMed ID: 19483647
[TBL] [Abstract][Full Text] [Related]
18. Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20+ Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study.
Sehn LH; Goy A; Offner FC; Martinelli G; Caballero MD; Gadeberg O; Baetz T; Zelenetz AD; Gaidano G; Fayad LE; Buckstein R; Friedberg JW; Crump M; Jaksic B; Zinzani PL; Padmanabhan Iyer S; Sahin D; Chai A; Fingerle-Rowson G; Press OW
J Clin Oncol; 2015 Oct; 33(30):3467-74. PubMed ID: 26282650
[TBL] [Abstract][Full Text] [Related]
19. The therapeutic use of rituximab in non-Hodgkin's lymphoma.
Marcus R; Hagenbeek A
Eur J Haematol Suppl; 2007 Jan; (67):5-14. PubMed ID: 17206982
[TBL] [Abstract][Full Text] [Related]
20. Treating chronic lymphocytic leukemia with obinutuzumab: safety and efficacy considerations.
Reda G; Orofino N; Cassin R; Sciumè M; Fattizzo B; Cortelezzi A
Expert Opin Drug Saf; 2016 Jun; 15(6):865-73. PubMed ID: 26967902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
